Clinical trial · Interventional
EDOCH Alternating With DHAP for New Diagnosed Younger MCL
EDOCH Alternating With DHAP Regimen Combined Rituximab or Not to Treat New Diagnosed Younger (Age≤65 Years) Mantle Cell Lymphoma in China: A Multicentre Phase III Trial
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to: 1. determine the efficiency of EDOCH (etoposide,dexamethasone,doxorubicin, cyclophosphamide and vincristine) alternating with DHAP (cisplatin, cytarabine and dexamethasone) regimen combined with rituximab or not in young mantle cell lymphoma patients (age≤65 years); 2. determine the efficiency of rituximab and thalidomide plus prednisone as maintenance regimens.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Mantle Cell Lymphoma | Mantle Cell Lymphoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (10)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cisplatin | Drug | Cisplatin | ALIAS |
| Cyclophosphamide | Drug | Cyclophosphamide | ALIAS |
| Cytarabine | Drug | Cytarabine | ALIAS |
| Dexamethasone | Drug | Dexamethasone | ALIAS |
| Doxorubicin | Drug | Doxorubicin | ALIAS |
| Etoposide | Drug | Etoposide | ALIAS |
| Prednisone | Drug | Prednisone | ALIAS |
| Rituximab | Drug | Rituximab | ALIAS |
Design
Arms and outcomes
Arms (10)
- type
- EXPERIMENTAL
- label
- Etoposide
- description
- 50 mg/m2, IV, d1-4
- interventionNames
- Drug: Etoposide
- type
- EXPERIMENTAL
- label
- Doxorubicin
- description
- 10 mg/m2, IV, d1-4
- interventionNames
- Drug: Doxorubicin
- type
- EXPERIMENTAL
- label
- Dexamethasone
- description
- 30 mg/d, d1-5
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * age≤65 years * diagnosis with mantle cell lymphoma * Ann Arbor stage II,III or IV * ECOG≤1 or if ECOG≥2 but recover after pretreatment. Exclusion Criteria: * with centre neural system involvement * serious complications such as uncontrolled diabetes, gastric ulcer or other serious angiocardiopathy determined by the physician * HIV positive or active HBV infection or other uncontrolled systematic infection * clinical central nervous dysfunction * serious surgery within 30 days * pregnancy or baby nursing period or un-contracepted child bearing period woman.
References
Publications (0)
Data not yet available